CMS Open Payments · Program Year 2024
Genesis Innovation Group, Inc.
Genesis Innovation Group, Inc. reported $136.00 across General Payments, Research, and Ownership to 1 physicians and teaching hospitals across 1 transactions.
- $136.00 Below-median payer
- All-tracks total
- 1 Below-median volume
- Transactions
- 1 Below-median reach
- Recipients
- #1903
- of 1,925 companies
Genesis Innovation Group, Inc. reported $136.00 across all CMS Open Payments tracks (General + Research + Ownership) to 1 physicians and teaching hospitals in Program Year 2024 - ranking #1903 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $136.00, averaging $136.00 per recipient.
Genesis Innovation Group, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
10/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer genesis-innovation-group-inc Genesis Innovation Group, Inc.
$136.00 · #1903/1,925 · 0.0% industry · PY2024
- TOT $136.00
- RANK #1903
- SHARE 0.0%
- TXN 1
- RCP 1
- CAT 1
- GEN $136.00
- TOP1 100.0%
- PY 2024
Volume peers
Nearest volume peer: Kinex Medical Company LLC ($133.04)
Genesis Innovation Group, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Genesis Innovation Group, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Genesis Innovation Group, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Food and Beverage" leads the 1-category general-payment breakdown below at $136.00 (100.0% of General Payments, 1 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Genesis Innovation Group, Inc. made 1 types of general payments. "Food and Beverage" is the largest category at $136.00, 100.0% of General Payments.
How Genesis Innovation Group, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $136.00 | 1 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $136.00 (100.0%) of $136.00 in this company's General Payments records across 1 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Genesis Innovation Group, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Krishna Vemulapalli
$136.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Genesis Innovation Group, Inc. ranks #1903 of 1,925 by total payments (bottom 1% by spend) but is notably more concentrated than that alone would suggest -- #130 of 1,838 by HHI (top 7% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Lumos Diagnostics, Inc. : $3.9K total payments, HHI 10000
- FKG Dentaire Sarl : $56.8K total payments, HHI 10000
- Gyder Surgical US Inc : $29.2K total payments, HHI 10000
- Fluxergy, Inc. : $10.2K total payments, HHI 10000
- Anser Implants Holding BV : $15.5K total payments, HHI 10000
- Midwest Medical Resources Inc : $1.0K total payments, HHI 10000
- Genesis Innovation Group, Inc. (this company) : $136.00 total payments, HHI 10000
- Jcbd, LLC : $65.3K total payments, HHI 10000
- Diagnostic Green GmbH : $36.0K total payments, HHI 10000
- Pixee Medical Inc. : $601.00 total payments, HHI 10000
- InSightec,LTD : $865.8K total payments, HHI 9998
- Edge Endo LLC : $91.1M total payments, HHI 9988
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Genesis Innovation Group, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Genesis Innovation Group, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Genesis Innovation Group, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Vy Spine LLC
Gunze International USA, Inc.
Elekta Pty Ltd
FUJIFILM Holdings America Corporation
Lifescan, Inc.
Put this to use
Genesis Innovation Group, Inc. ranks #1903 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Genesis Innovation Group, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.